Dare Bioscience (DARE) Debt Ratio (2013 - 2025)

Dare Bioscience's (DARE) quarterly Debt Ratio came in at 0.0 in Q3 2025, down 97.63% on a QoQ basis from 0.01 in Q2 2025.

Dare Bioscience (DARE) Debt Ratio (2013 - 2025) Analysis & Trends

Dare Bioscience (DARE) has 8 years of Debt Ratio data on file, last reported at 0.0 in Q3 2025.

Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 0.0 (changed N/A YoY) and the FY2024 annual result came in at 0.0, changed N/A from the prior year.
Debt Ratio slipped to 0.0 in Q3 2025, from 0.01 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.1 in Q1 2021 to a low of 0.0 in Q4 2024.
A 3-year average of 0.03 and a median of 0.01 in 2025 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	Dare Bioscience	11.91 Mn	-705,728.22	-132,343.00	-

Download Data